Navigation Links
Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
Date:3/1/2010

FREMONT, Calif., March 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.  This drug candidate, having a proprietary siRNA structure, is being developed for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).  The current trial represents the seventh clinical study of Quark synthetic siRNAs.  QPI-1007 has been evaluated in several preclinical models of ocular neuroprotection, and has been shown in these models to protect retinal ganglion cells from injury-induced apoptosis.

The study is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug will be given to all patients who participate.  This study will determine whether QPI-1007 is safe when it is injected into the eye and will also reveal if there are any side effects of the drug and how long it takes for the body to clear the drug.  In addition, the study will examine the biological activity of the drug in NAION patients.  The study will enroll patients in two strata, and is being conducted in the U.S. and Israel.  Stratum I will enroll legally blind patients, while stratum II will enroll patients with recent onset of NAION.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
2. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
3. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
4. Quark Pharmaceuticals Presents at Asia TIDES Conference
5. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
6. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
7. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015   AMC Health , ... showcase advances in monitored care that are transforming chronic ... ATA 2015 Conference, May 2-5 at the ... Health will share information about how their innovative ... help transform and personalize healthcare delivery at Booth #2116 ...
(Date:4/27/2015)... NEW YORK , April 27, 2015 ... claims against the board of directors of Aerie Pharmaceuticals, ... concerning whether the board has breached its fiduciary duties ... Company issued a press release announcing results from its ... things, the press release disclosed that in the trial, ...
(Date:4/27/2015)... 2015  USL di Reggio Emilia, the Regional Health ... has implemented Zebra Technologies Corporation (NASDAQ: ... Wireless Network Solution (WNS) provided by Zebra has ... in real time via mobile computers, contributing to improved ... also provides employee and guest Wi-Fi access and enables ...
Breaking Medicine Technology:AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... pharmaceutical,company dedicated to improving health through the development, manufacture ... the counter ("OTC"),products, today announced that it plans to ... 2009, after the market closes. , ...
... 9, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today ... , Arena reported a lower net loss allocable to common stockholders ... per share, compared to a net loss allocable to common stockholders ... per share, and a net loss allocable to common stockholders in ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9
(Date:4/27/2015)... 2015 According to a recent report ... after chronic back pain, TMJ disorders are the ... and disability. In addition, the report revealed that TMJ ... population, costing an estimated 4 billion dollars annually. , ... from seemingly unrelated symptoms such as headaches, neck pain, ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... NJ (PRWEB) April 27, 2015 ... firm, is proud to announce their sponsorship of ... Warren Counties. Girls on the Run is ... third through eighth grade. The program is delivered ... with uplifting workouts aimed to develop the whole ...
(Date:4/27/2015)... April 27, 2015 Ticket Down is ... at the Alpine Valley Music Theatre and the Isleta ... and Albuquerque, New Mexico area can celebrate because their ... the woods. Buffett will be performing alongside legendary ... His tour stops during the summer and fall months ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... ... contacted the Metropolitan Washington, DC Chapter of the Cystic Fibrosis (CF) Foundation 12 ... Melissa and 3-year old son Matthew had recently been diagnosed with the genetic ... age of survival for a child with CF was about 20 years. ...
... ... falling apart at home, psychotherapeutic interventions provide families with a growing array of options. ... (PRWEB) February 25, 2010 -- ... apart at home, psychotherapeutic interventions provide families with a growing array of options., , ,There ...
... ... braking system, affects millions of drivers , ... New York, NY (Lexis Nexis) February 25, 2010 -- The ... led to a significant increase in inquiries from individuals who are concerned about the ...
... A new study found that fluoxetine (Prozac) and ... collagen-induced arthritis (CIA) in mice. Research led ... Sussex Medical School (BSMS) in the UK studied ... selective serotonin reuptake inhibitors (SSRIs), most commonly used ...
... Special Issue of Business Horizons ( www.elsevier.com/locate/bushor ... Indiana University, and published by Elsevier, addresses issues central ... has been at the center of U.S. political debate ... support from Congress for passage of a national system ...
... ... ... ... ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Toyota Recalls Raise Awareness of Vehicle Safety Issues, Risks of Accidents from Driving Defective Automobiles 2Health News:Prozac and Celexa exhibit anti-inflammatory effects 2Health News:New Business Horizons special issue on US health care 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 3Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 4Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 5Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 6Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 7
... offers a range of standard, enhanced ... delivers therapy to meet the needs ... in commercial and clinical effectiveness and ... the SleepStyle 200 series is the ...
... The ResMed S6 Lightweight II CPAP ... microprocessor-controlled motor that maintains consistent pressure. ... and adjusting the settings easy, and ... and make adjustments is simple. This ...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
The S7 Elite is the premium device in ResMeds award-winning S7 series. All S7 devices include an option of integrated humidification....
Medicine Products: